Aethlon Medical

AEMD

Medical - Devices · Healthcare

Price

$2.17

-0.11 (-4.82%)

after-hours:$3.16+45.54%

Market Cap

$1.1M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+3553.6% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 18K (2022) → 674K (2026)

Winston Score History

The full picture

Aethlon Medical is a small medical device company that develops a blood filtration technology called the Hemopurifier. This device is designed to remove viruses and cancer-promoting particles directly from a patient's bloodstream, similar to how a dialysis machine filters waste. The company focuses on treating life-threatening viral infections and certain types of cancer.

Aethlon is a pre-revenue stage company, meaning it does not yet generate meaningful sales. It funds operations primarily through stock offerings and grants while pursuing FDA approval for its Hemopurifier device. Based in San Diego, California, the company has an extremely small market capitalization and operates at a significant loss. Its potential competitive advantage lies in its novel filtration approach, which has few direct competitors. The key risk is that the company must successfully complete clinical trials and obtain regulatory clearances to become commercially viable, with no guarantee of approval or future profitability.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+95.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↓ Declining (-14% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

10.7%ownership

Insiders own a meaningful stake in the company

Cash Runway

~9 months

$5M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Aethlon Medical has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-129.8%

Weak — -129.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

8/8 quarters

Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.05

Conservative — low debt load (0.05)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial